Equibles does not estimate personal net worth.
Get an email with a short summary when Heron Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get HRTX alertsMark Hensley is recorded as COO at Heron Therapeutics, Inc. (HRTX). The newest filing on record that lists Mark Hensley as COO at Heron Therapeutics, Inc. (HRTX) is dated April 30, 2026. Heron Therapeutics, Inc. reported in an 8-K filed April 29, 2025 that Mark Hensley was appointed Chief Operating Officer, effective April 28, 2025. The proxy statement of Heron Therapeutics, Inc. reports total compensation of $4,307,500 for Mark Hensley in fiscal 2025, including a base salary of $372,212. Disclosed compensation is on record for 3 fiscal years. Mark Hensley has spoken on 5 earnings calls across 1 company, most recently for Heron Therapeutics, Inc. on August 10, 2026. Heron Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Heron Therapeutics, Inc. includes Craig Collard (CEO and Board Member), Adam Morgan (Chairman and Board Member), Ira Duarte (CFO and Chief Accounting Officer) and 7 others.
“On April 28, 2025, Heron Therapeutics, Inc. (the "Company") announced that it appointed Mark Hensley as Chief Operating Officer, effective April 28, 2025 (the "Effective Date").”
“Starting on slide six with the overall net sales picture. Total net sales of $37.7 million in the second quarter, up from $34.7 million in the first quarter. On the acute care side, 15.3 million combined.”
“Moving to product performance, starting with our overall net sales picture for the quarter. This chart shows quarterly net revenue for each product across the last four quarters.”
“I'll start with acute care, where we finish the year with clear momentum, and then I'll close with oncology-supportive care. Moving now to slide 6. Acute care net sales were $16.3 million in the fourth quarter, up from $12.3 million in the third quarter, an increase of about 33%.”
“In acute care, ZYNRELEF kept its momentum in the third quarter. This is a site-by-site, case-by-case adoption curve. Access enables OR-proved converts, protocols make it stick.”
“Q2 was a transitional quarter for Heron as we implemented several key commercial changes designed to strengthen execution in the second half of the year and beyond.”
Start not stated–present
Last confirmed April 30, 2026
Biotechnology · Healthcare
COO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Heron Therapeutics, Inc. (HRTX) | EVP, Chief Operating Officer | $372,212 | $4,307,500 |
| 2024 | Heron Therapeutics, Inc. (HRTX) | EVP, Chief Operating Officer | — | — |
| 2023 | Heron Therapeutics, Inc. (HRTX) | EVP, Chief Operating Officer | — | — |
